TC BioPharm (Holdings) plc Warrants (TCBPW)
$0.01
As on 21-Mar-2025 16:25EDT
Market cap
$-- Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-5.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0
-
Debt to Equity
0.7
-
Book Value
$0.8
-
EPS
$-1.7
-
Face value
--
-
Shares outstanding
0
5 Years Aggregate
CFO
£-40.82 Mln
EBITDA
£-45.67 Mln
Net Profit
£-34.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TC BioPharm (Holdings) plc Warrants (TCBPW)
| -39.4 | -64.9 | -60.3 | -84.1 | -75.3 | -- | -- |
|
BSE Sensex*
| -11.7 | -4.8 | 1.1 | -8.2 | 3.9 | 5.1 | 10.0 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
TC BioPharm (Holdings) plc Warrants (TCBPW)
| -69.2 | -76.8 |
|
BSE Sensex
| 8.1 | 18.7 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TC BioPharm (Holdings) plc Warrants (TCBPW)
|
0.0 | -- | 0.0 | -5.9 | -- | -391.6 | -- | 0.0 |
| 1.4 | 73.5 | 0.0 | -9.0 | -- | -263.8 | -- | 6.1 | |
| 13.0 | 809.3 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 21.5 |
Shareholding Pattern
View DetailsAbout TC BioPharm (Holdings) plc Warrants (TCBPW)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified... gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Read more
-
CEO & Director
Mr. Bryan Leland Kobel
-
CEO & Director
Mr. Bryan L. Kobel
-
Headquarters
Motherwell
-
Website
FAQs for TC BioPharm (Holdings) plc Warrants (TCBPW)
What is the current share price of TC BioPharm (Holdings) plc Warrants (TCBPW) Today?
The share price of TC BioPharm (Holdings) plc Warrants (TCBPW) is $0.01 (NASDAQ) as of 21-Mar-2025 16:25 EDT. TC BioPharm (Holdings) plc Warrants (TCBPW) has given a return of -75.34% in the last 3 years.
What is the current PB & PE ratio of TC BioPharm (Holdings) plc Warrants (TCBPW)?
Since, TTM earnings of TC BioPharm (Holdings) plc Warrants (TCBPW) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.02 |
0.04 |
2022 |
-1.46 |
5.81 |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of TC BioPharm (Holdings) plc Warrants (TCBPW)?
The 52-week high and low of TC BioPharm (Holdings) plc Warrants (TCBPW) are Rs -- and Rs -- as of 13-Sep-2026.
What is the market cap of TC BioPharm (Holdings) plc Warrants (TCBPW)?
TC BioPharm (Holdings) plc Warrants (TCBPW) has a market capitalisation of -- as on 21-Mar-2025. As per SEBI classification, it is a company.
Should I invest in TC BioPharm (Holdings) plc Warrants (TCBPW)?
Before investing in TC BioPharm (Holdings) plc Warrants (TCBPW), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.